Last reviewed · How we verify
tumor necrosis factor
At a glance
| Generic name | tumor necrosis factor |
|---|---|
| Sponsor | National Institutes of Health Clinical Center (CC) |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (PHASE2, PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) (PHASE3)
- Pro- and Anti-inflammatory Cytokines in PCOS
- Physical Exercise and Biomolecular Analysis to Reduce Uremic Toxins in Chronic Kidney Disease: An Exploratory Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |